DURECT to Present at the BMO Capital Markets Healthcare Conference

CUPERTINO, Calif., July 28 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX) announced today that Matthew Hogan, Chief Financial Officer,
will be presenting at the BMO Capital Markets 9th Annual Focus on Healthcare
Conference on Wednesday, August 5 at 4:00 pm Eastern Time. The conference is
being held at the Millennium Broadway Hotel in New York City. A webcast of
the presentation will be accessible at:
http://www.bmocm.com/conferences/2009healthcare/webcast/.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing
innovative drugs for pain and other chronic diseases, with late-stage
development programs including REMOXY , POSIDUR(TM), ELADUR(TM), and
TRANSDUR(TM)-Sufentanil. DURECT’s proprietary oral, transdermal and
injectable depot delivery technologies enable new indications and superior
clinical/commercial attributes such as abuse deterrence, improved convenience,
compliance, efficacy and safety for small molecule and biologic drugs. For
more information, please visit www.www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM) are
trademarks of DURECT Corporation. Other referenced trademarks belong to their
respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug
candidates under development and have not been approved for commercialization
by the US Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation

07/28/2009
CONTACT: Matthew J. Hogan, Chief Financial Officer of DURECT
Corporation, +1-408-777-4936
Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Web Site: http://www.www.durect.com